9 /100
LOW RISK
Score updated Jul 13, 2026

VRTX — Vertex Pharmaceuticals Incorporated Dilution Risk Tracker

Track VRTX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track VRTX — Get alerts when the score changes →

As of July 13, 2026, Vertex Pharmaceuticals Incorporated (VRTX) has a DilutionWatch DilutionScore of 9/100, rated LOW dilution risk. Vertex Pharmaceuticals Incorporated has a market capitalization of $113.59B, 253.81M shares outstanding, 1698 institutional holders tracked. Key dilution vectors include approximately 999 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
20
💰 Cash Runway
0
📊 Float Risk
0
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for VRTX.
🔔 Track VRTX — Get forecast alerts →

💹 Market Data

Market Cap$113.59B
Shares Outstanding253.81M
Float253.02M
Cash$7.25B
Debt$105.00M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 20.0% shares (2026Q1 vs prior)
1698 institutional holders · 294.36M shares
#1 VANGUARD CAPITAL MANAGEMENT LLC 33.03M shares
#2 Capital World Investors 25.37M shares
#3 BlackRock, Inc. 23.97M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest4.94M
Days to Cover2.0
% of Float1.9%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2013
4 INSIDER TRANSACTION Apr 17, 2026
4 INSIDER TRANSACTION Apr 17, 2026
4 INSIDER TRANSACTION Apr 17, 2026
4 INSIDER TRANSACTION Mar 31, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for VRTX Shareholders

Vertex Pharmaceuticals Incorporated (VRTX) has a DilutionScore of 9/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 13, 2026.

DilutionWatch's EDGAR monitoring for VRTX shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for VRTX in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for VRTX alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track VRTX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking VRTX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for VRTX
📊 VRTX FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 VRTX Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.